上-下气道慢性炎症性疾病联合诊疗与管理专家共识

2017-07-11 中华医学会呼吸病学分会哮喘学组 中华医学杂志.2017,97(26):2001-2022.

上-下气道慢性炎症性疾病是指炎症累及上和(或)下气道的慢性疾病,其中包括:(1)以上气道为主的疾病:如变应性鼻炎(AR)、非变应性鼻炎(NAR)、慢性鼻-鼻窦炎(CRS)、上气道咳嗽综合征(UACS)、鼻息肉病、腺样体肥大等;(2)以下气道为主的疾病:如支气管哮喘(简称哮喘)、支气管扩张症(简称支扩)、慢性阻塞性肺疾病(简称慢阻肺)、慢性咳嗽、弥漫性泛细支气管炎(DPB);(3)上-下气道炎症并存

中文标题:

上-下气道慢性炎症性疾病联合诊疗与管理专家共识

发布日期:

2017-07-11

简要介绍:

上-下气道慢性炎症性疾病是指炎症累及上和(或)下气道的慢性疾病,其中包括:(1)以上气道为主的疾病:如变应性鼻炎(AR)、非变应性鼻炎(NAR)、慢性鼻-鼻窦炎(CRS)、上气道咳嗽综合征(UACS)、鼻息肉病、腺样体肥大等;(2)以下气道为主的疾病:如支气管哮喘(简称哮喘)、支气管扩张症(简称支扩)、慢性阻塞性肺疾病(简称慢阻肺)、慢性咳嗽、弥漫性泛细支气管炎(DPB);(3)上-下气道炎症并存性疾病:如阿司匹林哮喘(AIA)、不动纤毛综合征、鼻窦支气管综合征(SBS)、变应性支气管肺曲霉菌病(ABPA)、囊性纤维化、坏死性肉芽肿性血管炎、变应性肉芽肿性血管炎(Churg-Strauss综合征,CSS)、复发性多软骨炎等。上-下气道炎症并存性疾病多与遗传因素有关,在中国的发病率尽管不及欧洲人或高加索人种高,但也非罕见。 上述疾病在遗传学、免疫学、解剖学、流行病学、病理生理、临床表现、治疗思路上均有不同程度的关联但由于学科划分的原因,上述疾病在临床上分属于呼吸科、儿科、耳鼻咽喉科、变态反应科、皮肤科和消化科。专科医师更多关注本专科疾病的表现与诊断,常常忽略该类疾病在其他部位的表现和处理,极大地影响了各科医师对这类疾病的全面认识和系统管理。因此中华医学会呼吸学分会哮喘学组牵头召集呼吸科、耳鼻咽喉头颈外科、儿科、变态反应科等相关领域专家,结合国内外最新的循证医学依据,制订本共识,旨在帮助首诊医师对于上-下气道慢性炎症性疾病作出正确诊断及合理处理,以提高疗效、避免重复用药、减少药物不良反应和患者的经济负担。

 

拓展指南:气道相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067142, encodeId=78bc106e142f6, content=学习了,希望早点更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Nov 05 06:20:01 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967683, encodeId=edd196e683eb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8235505951, createdName=钟余霞, createdTime=Sat May 22 11:22:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951967, encodeId=4b2795196eb9, content=好精彩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Mon Mar 29 07:27:02 CST 2021, time=2021-03-29, status=1, ipAttribution=)]
    2021-11-05 未来将来

    学习了,希望早点更新

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067142, encodeId=78bc106e142f6, content=学习了,希望早点更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Nov 05 06:20:01 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967683, encodeId=edd196e683eb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8235505951, createdName=钟余霞, createdTime=Sat May 22 11:22:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951967, encodeId=4b2795196eb9, content=好精彩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Mon Mar 29 07:27:02 CST 2021, time=2021-03-29, status=1, ipAttribution=)]
    2021-05-22 钟余霞

    好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067142, encodeId=78bc106e142f6, content=学习了,希望早点更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Nov 05 06:20:01 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967683, encodeId=edd196e683eb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8235505951, createdName=钟余霞, createdTime=Sat May 22 11:22:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951967, encodeId=4b2795196eb9, content=好精彩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37e5423044, createdName=ms6000000252401279, createdTime=Mon Mar 29 07:27:02 CST 2021, time=2021-03-29, status=1, ipAttribution=)]
    2021-03-29 ms6000000252401279

    好精彩

    0